Antiarrhythmic drugs. Part 3: rate-control drugs release_xmoe6atz7bfejbf7y6sk4s5xai

by Michael Sampson

Published in British Journal of Cardiac Nursing by Mark Allen Group.

2019   Volume 14, Issue 11, p1-11

Abstract

Rate-control drugs are used to reduce the ventricular rate during atrial arrhythmias and are widely used in both primary and secondary care. In this final instalment of a three-part article series, we evaluate three commonly used rate-control agents: bisoprolol, diltiazem, and digoxin. Of these, bisoprolol has the widest range of indications as it is also used in the prevention of ventricular arrhythmias. It has the best safety profile of the three drugs owing to its combined renal and hepatic excretion. Diltiazem and digoxin have a narrower range of use and carry a greater risk of toxicity as a result of their reliance on either hepatic or renal elimination. These issues are explored alongside consideration of evidence base for use, dosing, and interactions. The focus is on information that supports safe prescribing and administration.
In application/xml+jats format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.

"Dark" Preservation Only
Save Paper Now!

Know of a fulltext copy of on the public web? Submit a URL and we will archive it

Type  article-journal
Stage   published
Date   2019-11-02
Language   en ?
Journal Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  1749-6403
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 782cbde9-b40c-48ad-8219-8d818e33a49d
API URL: JSON